Abstract
Introduction: Primary and secondary prevention of cardiovascular Disease (CVD) are major concerns and priorities. The best tools that we actually have to prevent CVD are the biomarkers. Numerous studies have shown that the presentation of cardiac disease in women is quite different from the presentation in men. Thus, one question arises “Are there any differences in biomarkers as well?” The answer to this question could open new avenues for a tailored management of cardiac diseases. Method and Results: We searched the PubMed and Medline databases for articles comparing differences between the 2 genders in terms of biomarker expression. Keywords used included “Cardiovascular biomarkers sex differences”. We reviewed the role of different biomarkers in the 2 genders in relation to cardiac events. Conclusions: Differences of expressions in biomarker levels were found between the 2 genders. Further investigation should be promoted.
Keywords: Cardiovascular biomarkers, gender differences.
Current Vascular Pharmacology
Title:Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Volume: 11 Issue: 5
Author(s): Erjon Agushi, Borejda Xhyheri and Raffaele Bugiardini
Affiliation:
Keywords: Cardiovascular biomarkers, gender differences.
Abstract: Introduction: Primary and secondary prevention of cardiovascular Disease (CVD) are major concerns and priorities. The best tools that we actually have to prevent CVD are the biomarkers. Numerous studies have shown that the presentation of cardiac disease in women is quite different from the presentation in men. Thus, one question arises “Are there any differences in biomarkers as well?” The answer to this question could open new avenues for a tailored management of cardiac diseases. Method and Results: We searched the PubMed and Medline databases for articles comparing differences between the 2 genders in terms of biomarker expression. Keywords used included “Cardiovascular biomarkers sex differences”. We reviewed the role of different biomarkers in the 2 genders in relation to cardiac events. Conclusions: Differences of expressions in biomarker levels were found between the 2 genders. Further investigation should be promoted.
Export Options
About this article
Cite this article as:
Agushi Erjon, Xhyheri Borejda and Bugiardini Raffaele, Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events, Current Vascular Pharmacology 2013; 11 (5) . https://dx.doi.org/10.2174/1570161111311050017
DOI https://dx.doi.org/10.2174/1570161111311050017 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Current Drug Targets Rewiring the Heart: Stem Cell Therapy to Restore Normal Cardiac Excitability and Conduction
Current Stem Cell Research & Therapy Cardiomyocyte-Specific TβR2 Knockout Mice are More Susceptible to Cardiac Hypertrophy Induced by Adrenergic Agonist Stimulation
Current Molecular Medicine Cellular Therapy for Myocardial Repair
Current Cardiology Reviews Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Hydrogels: A Journey from Diapers to Gene Delivery
Mini-Reviews in Medicinal Chemistry Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design Risk Factors for Heart Failure Progression and Outcomes
Current Cardiology Reviews Respiratory Gas Exchange During Exercise in Children with Congenital Heart Disease: Methodology and Clinical Concepts
Current Respiratory Medicine Reviews Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Current Molecular Pharmacology Amniotic Fluid Embolism: Moving Diagnosis Through the Time. From the Mechanical Pulmonary Vascular Occlusion Until An Immuno - Inflammatory Pathogenesis?
Current Pharmaceutical Biotechnology